Business Standard

Glenmark Pharma hits four-year high, surges 10% in two days

The company has entered into an agreement with Forest Labs to develop novel mPGES-1 inhibitors to treat chronic inflammatory conditions, including pain.

Related News

Glenmark Pharmaceuticals has rallied over 5% to Rs 547, its highest level since September 2008, with heavy volumes on the NSE. The stock opened at Rs 522 and has seen a combined 1.28 million shares changing hands on the counter so far compared to less than one million shares that were traded daily in past two weeks.

The stock has outperformed the market by surging 10% in past two trading sessions compared to 1% rise in benchmark Sensex after the company informed the stock exchanges that it has entered into an agreement with (Forest Labs) to develop novel mPGES-1 inhibitors to treat chronic inflammatory conditions, including pain.

Under the terms of agreement, Forest Labs will make a $6-million up-front payment and provide an additional $3 million to support the next phase of work. Forest Labs will make other future payments in FY2014 to support the ongoing mPGES-1 inhibitors programme.

Analyst at Sharekhan recommended a BUY on the stock with the revised target price of Rs 600 saying that it an important development for the company having positive repercussions in the long term.

Read more on:   
|
|

Read More

Two entities fail to make prima facie case to revoke ban: Sebi

The Securities and Exchange Board of India (Sebi) today said the restraining order on two entities, related to plunge in some mid-cap stocks in July, ...

Quick Links

 

Market News

Mustardseed down 0.9% on subdued spot demand

Delivery in far-month October contracts fell by 0.76%

DLF extends losses post SC order to pay Rs 630 cr penalty

This is following a case related to abuse of market dominance

PSU Banks drop after Mumbai EOW uncovers fraud

PSU banks have dropped after the Mumbai EOW busted a largescale banking racket amounting to Rs 1000 crore

Nifty facing stiff resistance around 7,970; DLF down 2%

Gains were led by select index heavyweights even as DLF continued to witness profit taking after SC directive to pay penalty

Turmeric rises 1% on export demand

Speculators enlarge positions, taking positive cues from the spot market

Back to Top